Form 4: Zevra Therapeutics CFO LaDuane Clifton Sells 11,000 Shares
SEC Form 4 Filing
CFO & Treasurer of Zevra Therapeutics, R. LaDuane Clifton, sold 11,000 shares of common stock at $7.861 per share on February 13, 2025, according to a Form 4 filing.
Summary
- On February 13, 2025, R. LaDuane Clifton, the CFO & Treasurer of Zevra Therapeutics, sold 11,000 shares of the company's common stock.
- The sale was executed at a price of $7.861 per share.
- Following the transaction, Clifton directly owns 51,361 shares of Zevra Therapeutics.
- The transaction was made pursuant to a pre-arranged 10b5-1(c) plan adopted on October 15, 2024.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine disclosure of an insider stock sale. The existence of a 10b5-1 plan suggests the sale was pre-planned.
Industry Context
Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their trading activities. The sale could be for personal financial planning reasons and may not necessarily reflect a negative outlook on the company.
Stakeholder Impact
- The stock sale by a key executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 10/15/2024 | Adoption date of the 10b5-1(c) plan |
| 02/13/2025 | Date of the stock sale transaction |
| 02/14/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.